Autopsy report · NCT01929954

Safety Study of Gintuit™ in Subjects Requiring Socket Grafting

“Changes in corporate business environment”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 8 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Organogenesis

Sponsor type

Industry

Conditions

Edentulous Alveolar Ridge

Interventions

Gintuit; Bio-Gide

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• Evaluation of Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft in Treatment of Partial Thickness Thermal Burns
  “Change in company strategy.” (69% match in meaning)
• ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
  “Business strategy change” (69% match in meaning)
• Automated Breast Ultrasound Case Collection Registry
  “Change in business strategy” (68% match in meaning)
• Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea
  “Change in company priorities” (66% match in meaning)
• Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
  “Company development strategy change” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.